Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
IPO Year: 2014
Exchange: NASDAQ
Website: adverum.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2024 | $25.00 | Outperform | Oppenheimer |
| 4/30/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/7/2022 | $4.00 | Hold → Buy | Truist |
| 7/23/2021 | Hold → Neutral | Cantor Fitzgerald | |
| 7/23/2021 | $23.00 → $3.00 | Overweight → Neutral | Cantor Fitzgerald |
| 7/23/2021 | $5.00 → $2.00 | Market Perform | SVB Leerink |
S-8 - Adverum Biotechnologies, Inc. (0001501756) (Filer)
8-K - Adverum Biotechnologies, Inc. (0001501756) (Filer)
DEFA14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)
SCHEDULE 13D - Adverum Biotechnologies, Inc. (0001501756) (Subject)
10-Q - Adverum Biotechnologies, Inc. (0001501756) (Filer)
8-K - Adverum Biotechnologies, Inc. (0001501756) (Filer)
SCHEDULE 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
DEFA14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)
DEF 14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)
PRE 14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)
4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00
H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00
Truist upgraded Adverum Biotech from Hold to Buy and set a new price target of $4.00
Cantor Fitzgerald downgraded Adverum Biotech from Hold to Neutral
Cantor Fitzgerald downgraded Adverum Biotechnologies from Overweight to Neutral and set a new price target of $3.00 from $23.00 previously
SVB Leerink reiterated coverage of Adverum Biotechnologies with a rating of Market Perform and set a new price target of $2.00 from $5.00 previously
SVB Leerink downgraded Adverum Biotech from Outperform to Mkt Perform and set a new price target of $5.00
Chardan Capital downgraded Adverum Biotechnologies from Buy to Neutral and set a new price target of $5.00 from $20.00 previously
Truist downgraded Adverum Biotech from Buy to Hold and set a new price target of $9.00 from $30.00 previously
RBC Capital Mkts downgraded Adverum Biotech from Outperform to Sector Perform and set a new price target of $6.00
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
MIAMI, July 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, July 16, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go
MIAMI, July 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1July 16, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the registra
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $2.22 per share, equal to the per share closing price of Adverum's common st
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the first quarter of 2025. The company also provided pipeline highlights and a
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common
REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. "We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a potential best-in-class, one-and-done gene therapy. Ixo-vec offers the potential for life-long vision preservation and a favorable safety profile and is overwhelmingly preferred by patients over tod
REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $3.83 per share, Adverum's closing trading price on the grant date, and will vest over four years,
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET. The webcast of the fireside chat may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the event. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ:AD
Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS is the first-ever initiation of a registrational intravitreal gene therapy trial in patients with wet AMDNon-inferiority study to evaluate a single Ixo-vec injection compared to on-label aflibercept 2mg in both treatment-naïve and previously treated patients REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today announ
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,380 shares of common stock and restricted stock units (RSUs) for 22,790 shares of common stock to 5 new employees under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $4.20 per share, Adverum's closing
- 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec
- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reporte
REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Company's executive leadership team as chief medical officer and Dr. Szilárd Kiss to the Company's Board of Directors. Dr. Ozden has stepped down from the Company's Board of Directors, with Dr. Kiss filling the existing Board seat. "Adverum has made significant progress in demonstrating Ixo-vec's potential best-in-class profile for patients with wet AMD. As we advance Ixo-vec through the LUNA trial and
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald "Romu" Corbau, Ph.D., has joined Adverum as the company's chief scientific officer. Dr. Corbau will serve as a member of Adverum's executive committee. "On behalf of the entire team at Adverum, I am delighted to welcome Dr. Corbau as the newest member of our executive leadership team. Romu has spent the majority of his career working to deliver on the promise of gene therapy. Earlier in his career, Romu led Spark Therapeutics' translati
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial - - Reported OPTIC long-term follow-up data demonstrating that patients continue to experience substantial, long-term benefit from Ixo-vec through 3 years of follow-up - - Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 - - Cash runway projected into 2025 - REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of car
REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical experience, a proven track record in drug development, and deep experience in ophthalmology, most recently as chief research and development officer at Allergan. "We are excited to welcome David to Adverum's Board of Directors. He brings an exceptional breadth of experie
REDWOOD CITY, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that R. Andrew "Andy" Ramelmeier, Ph.D., has joined Adverum as the company's chief technology officer. Dr. Ramelmeier will serve as a member of Adverum's executive committee and will lead Adverum's technology and operations organization, including process development and assay development for Adverum's investigational gene therapy ixoberogene soroparvovec (Ixo-vec). Ixo-vec is currently being evaluated in the Phase 2 LUNA trial as a potential one-time
REDWOOD CITY, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., as independent members of Adverum's Board of Directors. Dr. Ozden joins with two decades of experience in ophthalmology, clinical development and operations, pharmacovigilance, regulatory affairs and gene therapy. Ms. Hong brings a deep expertise in human capital management, executive and leadership development as well as executive and board compensation design and governance serving rapidly growing organizatio
- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration - REDWOOD CITY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Richard Beckman, M.D., has joined Adverum as the company's chief medical officer (CMO). Dr. Beckman will serve as a member of Adverum's executive committee and will report to Laurent Fischer, M.D., president and chief executive officer. Dr. Beckman will provide leadership for the company's gl
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou
-- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host conference call and webcast today at 1:30 pm PT / 4:30 pm ET -- REDWOOD CITY, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided an update on the ADVM-022 development program following a thorough review of data available from the INFINITY clinical trial in patients with diabetic macular edema (DME) and the OPTIC clinical trial in patients with we
SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13D/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)